ccr2/ccr5 antagonist bms-813160
Generic: CCR2/CCR5 Antagonist BMS-813160
ccr2/ccr5 antagonist bms-813160: 2 clinical trials tracked.
ccr2/ccr5 antagonist bms-813160 evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about ccr2/ccr5 antagonist bms-813160, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (2)
Tisch Cancer Institute - BMS Study # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-inhibitor) or BMS-986253 (Anti-IL-8) for NSCLC or HCC
Primary endpoint: Major Pathologic Response (MPR)
InterventionalRandomizedopen48 enrolledStarted 2020-03Completion 2028-071 site · United StatesIcahn School of Medicine at Mount Sinai
A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
Primary endpoint: Number of Participants Experiencing Adverse Events (AEs)
InterventionalRandomizedopen332 enrolledStarted 2017-08Completion 2023-0640 sites · Australia, Belgium, Canada, Germany…Bristol-Myers Squibb